HD-OPM Archive
Topics › Supplements & vitamins

Niacin (nicotinic acid) showed promise in a small Parkinson's trial, likely via brain NAD

Louis Nervegna · Jun 25, 2026 · ♥ 1 reactions · 0 comments · original Facebook post
Supplements & vitaminsBrain health & dementia
AI summary & key facts

Louis highlights a small 2021 human trial of niacin in Parkinson's disease, noting it is the form of vitamin B3 once used to lower cholesterol and that benefit may work through raising NAD in the brain. Nicotinamide riboside has similar small-trial results, including a 2023 high-dose safety trial.

Vitamin B3 in the form of niacin (nicotinic acid) might treat Parkinson’s disease.

These results come from a small human trial published in 2021.

Link to full study:

Paper · Front. Aging Neurosci. · 2021Niacin Enhancement for Parkinson’s Disease: An Effectiveness TrialWe previously reported that individuals with Parkinson’s disease (PD) present with lower vitamin B3 levels compared to controls. It may be related to carbidopa interaction, defective tryptophan metabolism, and stresses of night sleep disorder. Vitamin B3 is the energy source for all cells by producing NAD + and NADP + in redox reactions of oxidative phosphorylation. Thus, some symptoms of PD such as fatigue, sleep…frontiersin.org

This is the same form of vitamin B3 used in the past to lower cholesterol.

The mechanism appears to involve raising levels of NAD in the brain.

Note:

The nicotinamide riboside (NR) form of vitamin B3 might also treat Parkinson’s. These results also come from small human trials. Again, the mechanism appears to involve NAD. See links below.

Cure Parkinson'sNicotinamide riboside for Parkinson's: pilot results published - Cure Parkinson'sResearchers in Norway have published the promising results of a pilot clinical study of nicotinamide riboside for people with Parkinson's. Researchers in Norway have published the promising results of a pilot clinical study of nicotinamide riboside in people with Parkinson's.cureparkinsons.org.uk medicalnewstoday.comParkinson's disease: NR, a form of vitamin B3, may help with symptomsRecent research suggests that taking supplements of NR, a form of vitamin B3, could lead to symptom improvement in people with Parkinson's disease.medicalnewstoday.com Paper · Cell MetabolismCell Metabolism articlecell.com Paper · Nat Commun · 2023NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.Nicotinamide adenine dinucleotide (NAD) replenishment therapy using nicotinamide riboside (NR) shows promise for Parkinson's disease (PD) and other neurodegenerative disorders. However, the optimal dose of NR remains unknown, and doses exceeding 2000 mg daily have not been tested in humans. To evaluate the safety of high-dose NR therapy, we conducted a single-center, randomized, placebo-controlled, double-blind,…pmc.ncbi.nlm.nih.gov

Quoted:

32 men and 15 women with an average age of 62 years and a diagnosis of Parkinson's disease were enrolled in this double-blind study [1]. Along with their regular medications, they took daily supplements of either a placebo, 100 mg of niacin, or 250 mg of slow-release niacin. Each patient was assessed before treatment and after three months. Clinical assessments were carried out including disease-specific measures, such as the Unified Parkinson's Disease Rating Scale III (UPDRS) and more general quality of life measures, such as the Fatigue Severity Scale. Blood was also collected from the patients and analyzed for niacin plasma levels and inflammatory cytokines.

Following the results of the 3 month study, all subjects began taking 250 mg of slow-release niacin daily. If they were already on that regimen, they remained so for 9 more months for a total of one year. Those in the placebo and 100 mg groups took the 250 mg supplement for 12 more months. All measures were taken again after 12 months of 250 mg slow-release niacin.

The study's primary endpoint, the UPDRS, showed a high amount of variability at 3 months, but it improved from baseline at 12 months. Although there was no control group at the 12-month time point, scores improved by 3.5 points, while a decline of 5.5 points would have been expected over the same time period in a similar study population.

Many secondary measures also improved, including handwriting, perception of fatigue, mood, postural control, and frontal EEG rhythm. Several other measures, such as quality of sleep, did not change after 12 months of niacin treatment. These may or may not represent benefits, since declines might reasonably be expected based on disease progression. Only one measure was poorer compared to baseline, an assessment of visual attention and task switching known as the Trail Making Test.

“We have demonstrated the potential effectiveness of over-the-counter niacin enhancement as a proof of concept to support the well-being of individuals with PD. Vitamin B3 augmentation has the potential to maintain or improve symptoms. Based on the results of this effectiveness exploratory trial, a larger multicenter RCT is warranted.”

#vitaminb3HD #niacinHD #nadHD #parkinsonsHD #nrHD

Lifespan Research Institute | Building a Future Free of Age-Related DiseaseNiacin Tested Against Parkinson’s Disease | Lifespan Research InstituteA clinical trial on the effectiveness of niacin supplementation in Parkinson's disease patients has recently been published in Frontiers in Aging Neuroscience.lifespan.io

Research cited

← newer: Low-inflammatory diets linked to up to 30% lower dementia riolder: Take psyllium 2 hours apart from other medications; it also →